Zenas Biopharma Inc(ZBIO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -9.61 | Insider Own | 55.22% | Shs Outstand | 63.3M | Perf Week | 2.46% |
| Market Cap | 1.88B | Forward P/E | - | EPS next Y | 10.2% | Insider Trans | 0.33% | Shs Float | 29.2M | Perf Month | 7.51% |
| Enterprise Value | 1.62B | PEG | - | EPS next Q | -1.24 | Inst Own | 74.92% | Short Float | 42.95% | Perf Quarter | -10.85% |
| Income | -0.48B | P/S | 1875.13 | EPS this Y | 33.25% | Inst Trans | 22.25% | Short Ratio | 18.99 | Perf Half Y | 63.93% |
| Sales | 0.00B | P/B | 7.37 | EPS next 5Y | 23.61% | ROA | -97.39% | Short Interest | 12.54M | Perf YTD | -20.77% |
| Book/sh | 3.9 | P/C | 2.92 | EPS past 3/5Y | -39.47% - | ROE | -199.04% | 52W High | -35.49% ($44.60) | Perf Year | -4.7% |
| Cash/sh | 9.87 | P/FCF | - | Sales past 3/5Y | - | ROIC | -76.18% | 52W Low | 113.11% ($13.50) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -127.13% | Gross Margin | 96.9% | Volatility(W/M) | 5.92% 7.06% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 1621.6 | Sales Y/Y TTM | -93.33% | Oper. Margin | -27390.1% | ATR (14) | 1.87 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 9.93 | EPS Q/Q | -41.57% | Profit Margin | -48438.4% | RSI (14) | 54.29 | Recom | 1.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.93 | Sales Q/Q | - | SMA20 | 6.41% ($27.04) | Beta | -0.88 | Target Price | $47.88 |
| Payout | - | Debt/Eq | 1.58 | Earnings | 2026/8/13 | SMA50 | -2.78% ($29.59) | Rel Volume | 0.6 | Prev Close | $27.3 |
| Employees | 167 | LT Debt/Eq | 1.57 | EPS/Sales Surpr. | -57.71% -93.33% | SMA200 | 15.59% ($24.89) | Avg Volume(3M) | 0.66M | Price | $28.77 |
| IPO | 2024/9/13 | Option/Short | Yes/Yes | Trades | 5886 | Volume | 394,302 | Change | 5.38% |
🧬 Zenas BioPharma (ZBIO) is a late-stage clinical biotech company targeting autoimmune and inflammatory diseases. Its lead candidate, obexelimab, is a bifunctional antibody that simultaneously targets a B-cell surface antigen and an inhibitory receptor, pursuing a differentiated approach that modulates the immune response without depleting B cells. The company is expanding its pipeline across multiple indications, including IgG4-related disease, systemic lupus erythematosus, and multiple sclerosis.
Over the past 1 year, roughly in the middle
35% below its 1-year high.
Traded less than usual. That is 60% of its average volume.
ZBIO has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +33.3% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $187,513. Peers typically go for $1,237.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
43.0% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #110 of 594 in the industry
Based on market cap of $2B.
FAQ
What kind of company is ZBIO?
ZBIO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ZBIO?
The market cap of ZBIO is approximately $1.9B, ranking 2,112 within its sector.
What is the 52-week high and low for ZBIO?
ZBIO has recorded a 52-week high of $44.60 and a low of $13.50.
